Navigation Links
WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Date:11/7/2008

SHANGHAI, China, Nov. 7 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year, in vitro ADME collaboration agreement with Pfizer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

WuXi PharmaTech has enjoyed a close and cooperative relationship with Pfizer for many years, with collaborations ranging from synthetic chemistry, parallel medicinal chemistry (PMC), and ADME to bioanalytical services.

"This new agreement further strengthens our already productive relationship with Pfizer, one of our largest customers for many years, and it is the direct result of our research capability and firm commitment to quality and customer satisfaction," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

Under the new collaboration agreement WuXi PharmaTech in partnership with Pfizer will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer.

"A high quality and flexible Asia R&D partnership network is critical to Pfizer's emerging market and Asia strategy. We want to build strong relationship with leading Contract Research Organizations such as WuXi PharmaTech to tap into the scientific talents and R&D capabilities in Asia," commented Dr. Steve Yang, Vice President and Head of Asia R&D at Pfizer.

The evaluation of ADME properties is a key step in the drug discovery and development process. WuXi will evaluate ADME properties for Pfizer compounds with the goal of providing this key information to assist Pfizer scientists to improve the pharmacokinetic properties of their compounds.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceut
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
2. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
3. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
4. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
5. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
6. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
7. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
8. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
10. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
11. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2013)... 2013 In their latest Special ... Manufacturing of Injectable Drugs Through 2019,” PharmSource ... trends and plans for outsourcing commercially approved injectable ... database of the dose CMO industry - PharmSource’s ... Providers - the analytical model and assumptions are ...
(Date:12/5/2013)... get a major upgrade with the arrival of ... than today,s supercomputers. For the benefits of this ... however, quantum computers will need fast and efficient ... for science fiction, a team of researchers with ... National Laboratory (Berkeley Lab) have taken an important ...
(Date:12/5/2013)... , Dec. 5, 2013  KaloBios Pharmaceuticals, ... U.S. Patent and Trademark Office has issued ... of matter patent covering certain antibodies targeting ... (mAb), KB004.  The allowed claims relate to ... EphA3 receptor. (Logo: ...
(Date:12/5/2013)... cause of dementia among older people, yet there ... or prevent disease progression. A study online December ... Reports , published by Cell Press, provide interesting ... have successfully treated molecular signs of Alzheimer,s disease ... clinical studies. Whereas the compounds worked in non-neuronal ...
Breaking Biology Technology:New In-Depth Report on Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2019 2Berkeley Lab researchers create a nonlinear light-generating zero-index metamaterial 2Berkeley Lab researchers create a nonlinear light-generating zero-index metamaterial 3Berkeley Lab researchers create a nonlinear light-generating zero-index metamaterial 4KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4 2KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4 3KaloBios Receives Notice of Allowance for Key Composition of Matter Patent Covering KBOO4 4New study explains why promising dementia drugs failed in clinical trials 2
... AUSTIN, Texas, Oct. 25 (Nasdaq: VRML ... Oncology at the University of Kentucky,s Markey Cancer Center, ... today presented data demonstrating the high sensitivity of the ... Society Meeting being held in Prague, October 23-26. ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Japan, Oct. 25 Cellectis (Alternext: ALCLS), the French ... Research and Application (CiRA) of Kyoto University, Kyoto, Japan, ... collaboration to combine Cellectis, genome engineering technologies with CiRA,s ... natural characteristics of iPS cells for use as cellular ...
Cached Biology Technology:Dr. Fred Ueland, Markey Cancer Center, University of Kentucky Presents OVA1™ High Sensitivity Data at the 13th Annual International Gynecologic Cancer Society Meeting 2Dr. Fred Ueland, Markey Cancer Center, University of Kentucky Presents OVA1™ High Sensitivity Data at the 13th Annual International Gynecologic Cancer Society Meeting 3Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 2Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 3Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 4Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 5Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 6Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 7Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 8Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy 9Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 2Cellectis and the Center for iPS Cells Research and Application Enter Collaboration 3
(Date:12/6/2013)... for Collaborative Biotechnologies (ICB) has received an extension ... Laboratory-Army Research Office, providing an additional $48 million ... inspired by biological systems. The continuation in ICB ... of fundamental research in the areas of biotechnology, ... and medicine. , "This award extends the ICB ...
(Date:12/5/2013)... a million people with spinal cord injuries (SCI) in ... cases every year. Furthermore, it is estimated that there ... VA the largest integrated health care system in the ... researchers are still discovering all the various ways that ... paralysis. For example, researchers have long known that SCI ...
(Date:12/5/2013)... technique for the first time in mammalian brain cells, ... gene involved in building the circuitry that relays signals ... in the aging process in the brain, the researchers ... method, the discovery paves the way for faster progress ... as autism and schizophrenia as well as potential ...
Breaking Biology News(10 mins):Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million 2Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million 3Quadriplegics at risk for serious sleep breathing disorder 2Quadriplegics at risk for serious sleep breathing disorder 3Gene found to be crucial for formation of certain brain circuitry 2
... Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP), ... the 50th anniversary of the Society of Toxicology (SOT) at ... Lawrence Tabak, D.D.S., Ph.D., deputy director of ... among the many NIH leaders and research staff that will ...
... reporting the first evidence that consumption of a healthful antioxidant ... and does so by 10 percent. The new results, obtained ... research projects each year bolster similar findings on apple ... Journal of Agricultural and Food Chemistry . Zhen-Yu ...
... have long promoted biofuels produced from crop biomass ... A recent study questions whether the potential climate ... from land use management are considered. ... identify sources of greenhouse gas emissions. They found ...
Cached Biology News:NIH joins SOT to celebrate 50 years of toxicology science 2NIH joins SOT to celebrate 50 years of toxicology science 3